VECTIVBIO
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.
VECTIVBIO
Industry:
Biotechnology Health Care Medical
Founded:
2019-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.vectivbio.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
399 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Content Delivery Network Amazon
Similar Organizations
Bactobio
Bactobio is a biotechnology company unlocking biodiversity for a greener and safer world.
Dermavant Sciences
Dermavant Sciences is a biotechnology company focused on dermatology.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Kinarus Therapeutics (SIX:KNRS)
Kinarus is focused on developing novel treatments for patients suffering from serious viral, respiratory, and ophthalmic diseases.
mybacs
mybacs is a Biotechnology company specialized in the human microbiome.
Numab
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Ocean Biomedical
Ocean Biomedical is a biotechnology company that accelerates new discoveries in the world of medicine.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Q32 Bio
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Teitur Trophics
Teitur Trophics is a biotech company developing novel treatments for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-08-31 | Comet Therapeutics | Comet Therapeutics acquired by VectivBio | N/A |
Investors List
OrbiMed
OrbiMed investment in Post-IPO Equity - VectivBio
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - VectivBio
Forbion Capital Partners
Forbion Capital Partners investment in Post-IPO Equity - VectivBio
Vivo Capital
Vivo Capital investment in Post-IPO Equity - VectivBio
TCG Crossover
TCG Crossover investment in Post-IPO Equity - VectivBio
Driehaus Capital Management
Driehaus Capital Management investment in Post-IPO Equity - VectivBio
Eventide
Eventide investment in Post-IPO Equity - VectivBio
Frazier Life Sciences
Frazier Life Sciences investment in Post-IPO Equity - VectivBio
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Post-IPO Equity - VectivBio
Marshall Wace
Marshall Wace investment in Post-IPO Equity - VectivBio
Key Employee Changes
Official Site Inspections
http://www.vectivbio.com
- Host name: 172.67.74.109
- IP address: 172.67.74.109
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "VectivBio"
VectivBio 2025 Company Profile: Valuation, Investors
VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments …See details»
VectivBio — CTI Life Sciences
VectivBio AG is a late clinical-stage biotechnology company focused on rare conditions with well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed …See details»
VectivBio AG Information - RocketReach
VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed …See details»
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a ...
May 22, 2023 BOSTON & BASEL, Switzerland--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and …See details»
VectivBio Company Profile - Office Locations, Competitors ... - Craft
Jul 17, 2023 VectivBio a biotechnology company focused on the discovery, development, and commercialization of treatments for severe rare conditions. It develops transformational …See details»
VectivBio Company Profile | Management and Employees List
VectivBio Profile and History. VectivBio (Nasdaq: VECT) is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative …See details»
VectivBio - Overview, News & Similar companies | ZoomInfo.com
VectivBio's product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal diseases. ... Business …See details»
VectivBio AG Company Profile | Basel, BASEL-STADT, Switzerland ...
Find company research, competitor information, contact details & financial data for VectivBio AG of Basel, BASEL-STADT. Get the latest business insights from Dun & Bradstreet.See details»
VectivBio AG – Funding, Valuation, Investors, News - Parsers VC
May 31, 2024 VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. VectivBio …See details»
VectivBio - Forbion
VectivBio AG is a global, clinical-stage biotechnology company developing innovative treatments for severe rare conditions with significant unmet medical need. The company is committed to pursuing severe rare diseases with well …See details»
VectivBio taken over in $1bn acquisition
May 24, 2023 VectivBio’s lead candidate apraglutide, is a next-generation GLP-2 analogue is being tested in a Phase III trial with an anticipated readout of topline results by the end of this …See details»
VectivBio - Biotech Careers
VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. Their lead product …See details»
VectivBio Launches with $35M Financing to Bring Best-in
Jan 7, 2020 VectivBio is a global, clinical-stage biotechnology company focused on developing transformational therapeutics for patients living with serious, rare diseases. The company is …See details»
VectivBio - Contacts, Employees, Board Members, Advisors & Alumni
VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases. ... Experience the new Crunchbase, powered by AI . …See details»
Ironwood pays $1B for VectivBio and its phase 3 GI drug
May 22, 2023 The prize is VectivBio’s lead asset apraglutide, a GLP-2 analog in a late-stage trial for short bowel syndrome with intestinal failure (SBS-IF), for which a readout is due later this …See details»
VectivBio CEO and Key Executive Team | Craft.co
VectivBio's Founder and Chief Executive Officer and Board Member is Luca Santarelli. Other executives include Claudia D'Augusta, Chief Financial Officer; Alain Bernard, Chief …See details»
VectivBio Headquarters and Office Locations - Craft.co
VectivBio. Overview; Locations; Financials; Operating Metrics; Human Capital; Key People; Competitors; Supplier Risk; VectivBio Headquarters and Office Locations. Header placeholder …See details»
VectivBio's Leadership Team - Team members and org chart - The …
The current leadership team of VectivBio has a wealth of experience in the biotechnology industry. The Executive Director, Head of Strategic Planning, previously worked at Intercept …See details»
Ironwood to buy VectivBio for $1 billion | C&EN Global Enterprise
May 29, 2023 Ironwood Pharmaceuticals, a health-care firm focused on gastrointestinal disorders, will acquire VectivBio in a $1 billion all-cash deal. VectivBio specializes in …See details»
Swiss rare disease biotech VectivBio Holding files for a $100
Mar 19, 2021 VectivBio Holding, a Swiss Phase 3 biotech developing therapies for rare gastrointestinal disorders, filed on Friday with the SEC to raise up to $100 million in an initial …See details»